An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas

William H. Parker,Jonathan S. Berek,Elizabeth A. Pritts,David L. Olive,Andrew M. Kaunitz,Eva Chalas,Daniel L. Clarke‐Pearson,Barbara A. Goff,Robert E. Bristow,Hugh S. Taylor, Robin Farias‐Eisner,Amanda N. Fader,G. Larry Maxwell,Scott C. Goodwin, Susan M. Love,William E. Gibbons,Leland J. Foshag,Phyllis C. Leppert, Judy Norsigian,Charles W. Nager,Timothy D. Johnson, David S. Guzick,Sawsan As‐Sanie,Richard J. Paulson,Cindy Farquhar,Linda D. Bradley,Stacey A. Scheib,Anton J. Bilchik,Laurel W. Rice, Carla Dionne,Alison Jacoby,Charles Ascher‐Walsh,Sarah J. Kilpatrick,G. David Adamson,Matthew T. Siedhoff, Robert H. Israel, Marie Fidela R. Paraíso, Michael Frumovitz,John R. Lurain,Ayman Al-Hendy, Guy I. Benrubi,Steven S. Raman,Rosanne M. Kho,Ted L. Anderson,R. Kevin Reynolds,John O.L. DeLancey

Journal of Minimally Invasive Gynecology（2016）

引用 13|浏览2

暂无评分

摘要

In November, 2014 the Food and Drug Administration (FDA) ruled that power morcellation was contraindicated in “the majority of women” undergoing surgery for uterine myomas, owing to the potential risk of spreading occult uterine sarcoma. Although problems with this ruling were immediately apparent, the passage of time has allowed for more clarity on the related medical issues.

查看译文

关键词

MEDLINE,Medicine,Surgery,Food and drug administration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要